DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.

Autor: Wang, Weiqing¹ (AUTHOR), Agner, Bue F. Ross² (AUTHOR), Luo, Bin³ (AUTHOR), Liu, Lei⁴ (AUTHOR), Liu, Ming⁵ (AUTHOR), Peng, Yongde⁶ (AUTHOR), Qu, Shen⁷ (AUTHOR), Stachlewska, Karolina Amelia⁴ (AUTHOR), Wang, Guixia⁸ (AUTHOR), Yuan, Guoyue⁹ (AUTHOR), Zhang, Qiu¹⁰ (AUTHOR), Ning, Guang¹ (AUTHOR) guangning@medmail.com.cn

Publikováno v: Journal of Diabetes. Jun2022, Vol. 14 Issue 6, p401-413. 13p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.

Autor: Billings LK; Department of Medicine, NorthShore University HealthSystem/University of Chicago Pritzker School of Medicine, Evanston, IL, USA., Agner BFR; Novo Nordisk A/S, Søborg, Denmark., Altuntas Y; Endocrinology and Metabolism Clinic, University of Health Sciences, Şişli Hamidiye Etfal Teaching and Research Hospital, Istanbul, Turkey., Grøn R; Novo Nordisk A/S, Søborg, Denmark., Halladin N; Novo Nordisk A/S, Søborg, Denmark., Klonoff DC; Mills-Peninsula Medical Center, San Mateo, CA, USA., Tentolouris N; 1st Department of Propaedeutic Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, Medical School, Greece., Jódar E; Department of Endocrinology and Clinical Nutrition, University Hospital Quirónsalud Madrid & Ruber Juan Bravo, Universidad Europea de Madrid, Spain.

Publikováno v: Journal of diabetes science and technology [J Diabetes Sci Technol] 2021 May; Vol. 15 (3), pp. 636-645. Date of Electronic Publication: 2020 Feb 28.